Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 248-253

  Wolters, Bernd ^a   Müller, Tobias ^a   Ross, R Stefan ^a   Clauberg, Ralf ^a   Werfel, Uwe ^b   Roggendorf, Hedwig ^a   Siggelkow, Cornelius ^c   Hausen, Thomas ^c   Roggendorf, Michael ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Hospital Essen Mitte Huyssenstiftung   (Germany)

^c NONE

Author keywords

Age; Combined vaccine; HAV; HBV; Immunogenicity

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A ANTIGEN; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTENSION; IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY; THYROID DISEASE; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; GERMANY; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; VACCINES, COMBINED; YOUNG ADULT;

EID: 70349507292     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7051     Document Type: Article

References (31)

1. Castelli F, Carosi G, Tebaldi A, Pizzocolo G, Pisani S, Rossitto F, et al. Age specific anti-hepatitis A virus seropeidemiology in Italian travelers: indications for anti-hepatitis A vaccination. J Travel Med 1996; 3:214-8.
2. Koff RS. Seropeidemiology of hepatitis A in the United Stated. J Infect Dis 1995; 171:19-23.
3. Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R. Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 2001; 17:429-35.
4. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998; 128:111-4.
5. Cowcroft NS, Walsh B, Davidson KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 2001; 4:213-27.
6. WHO position paper on the use of hepatitis B vaccine. Weekly epidemiological record 2004; 28:255-63.
7. Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 2000; 18:1074-80.
8. Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, et al. A prospective, randomized US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix B®) in adults. Vaccine 2001; 19:4710-9.
9. Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines. A review of their immunogenicity and tolerability. Drugs 2003; 63:2625-49.
10. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001; 19:2055-60.
11. Thoelen S, Van Damme P, Leentvaar-Kuypers A, Leroux-Roels G, Bruguera M, Frei PC, et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999; 17:1657-62.
12. Ambrosch F, Wiedermann G, André FE, Delem A, Gregor H, Hofmann H, et al. Clinical and immunological investigation of a new combined hepatitis A and B vaccine. J Med Virol 1994; 44:452-6.
13. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Infect Dis Clin North Am 2006; 20:27-45.
14. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Inf Dis 2002; 35:1368-75.
15. Treadwell TL, Keeffe EB, Lake J, Read A, Friedman LS, Goldman IS, et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 1993; 95:584-7.
16. Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003; 21:3623-8.
17. Van Damme P, Van Herck K, Van der Wielen M. Letter to the Editor: Combined hepatitis A and B vaccine in elderly. Vaccine 2004; 22:303-4.
18. Junge U, Melching J, Dziuba S. Akute Hepatitis A trotz kombinierter Schutzimpfung gegen Hepatitis A und B. Dtsch Med Wochenschr 2002; 127:1581-3.
19. Genton B, D'Acremont V, Furrer HJ, Hatz C, Loutan L. Hepatitis A vaccine and the elderly. Travel Med Infect Dis 2006; 4:303-12.
20. Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: Comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006; 24:5509-15.
21. Nothdurft HD, Aumüller H, Aumüller R, Dames W, Stamer K, Kroetzsch H, et al. Letter to the Editor. Vaccine 2004; 22:592-3.
22. Stoffel M, Lievens M, Dieussaert I, Martin I, Andre F. Immunogenicity of Twinrix™ in older adults: a critical analysis. Expert Rev Vaccines 2003; 2:9-14.
23. Effros RB. Problems and solutions to the development of vaccines in the elderly. Immunol Allergy Clin N Am 2003; 23:41-55.
24. Grubeck-Loebenstein B. Changes in the aging immune system. Biologicals 1997; 25:205-8.
25. - T cell clonal expansions and an imbalance in the production oh Th1 and Th2 cytolines. J Immunol 2002; 168:5893-9.
26. Rapicetta M. Hepatitis B vaccination in dialysis centres: advantages and limits. Nephron 1992; 61:284-6.
27. Wagner D, Wagenbreth I, Stachan-Kunstyr R, Flik J. Failure of vaccination against hepatitis B with Gen H-B-Vax D in immunosuppressed heart transplant recipients. Clin Investig 1992; 70:585-7.
28. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines. Am J Prev Med 1998; 15:1-8.
29. Jilg W, Schmidt M, Deinhardt F. Four year experience with a recombinant hepatitis B vaccine. Infection 1989; 17:70-6.
30. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-13.
31. Renard D, Bruckers L, Molenberghs G, Vellinga A, Van Damme P. Repeated-measures models to evaluate a hepatitis B vaccination programme. Statist Med 2001; 20:951-63.